Cost of new “miracle” cancer pill sparks concern for some

A pill that extends life in metastatic pancreatic cancer now carries a sticker price that could buy a house.

Story Snapshot

The Food and Drug Administration approved Rasonque (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma after prior therapy or when chemo is not an option.
The company set a list price near $39,800 per month, about $477,000 a year.
Early data showed longer survival versus chemotherapy, driving hope and debate.
Coverage and out-of-pocket costs will hinge on insurance rules and assistance programs.

What The Approval Actually Covers

The Food and Drug Administration cleared Rasonque for adults with metastatic pancreatic adenocarcinoma who have already had at least one systemic therapy, or who cannot take multi-drug chemotherapy. The agency framed it as a new option in a cancer that offers few. That scope matters for families racing the clock. Doctors now have a targeted pill they can use after standard regimens fail. Regulators said yes months ahead of schedule, which signals urgency and strong clinical need.

Revolution Medicines will sell the pill once daily under the brand Rasonque. The company set a wholesale list price of about $39,800 for a 30-day supply, which comes to roughly $477,000 a year before discounts. Media latched onto that big number, and for good reason. It is one of the highest cancer drug launch prices yet, even in a market where most new therapies top $100,000 per year. Families hear that sticker price and think, “Who can pay that?”

What The Survival Signal Means

Trial results shared in coverage reported median overall survival of 13.2 months on daraxonrasib versus 6.7 months on chemotherapy in the broader study group, with a strong hazard ratio favoring the pill. In plain terms, the median patient lived about six and a half months longer on the new drug than on chemo. In pancreatic cancer, that is not a small win. It is time that lets someone see a holiday, handle affairs, or try the next therapy. That is why oncologists took notice.

Results like these do not erase tradeoffs. Targeted drugs can stop working as tumors adapt, and side effects can mount. But in a disease where options run thin and fast, doubling median survival in a studied group is rare air. Critics may ask if this is a cure. It is not. It is a tool that can add months for some patients, which is meaningful in this setting. That clinical value is the core of the price defense from the company and its backers.

The Price Shock, And What Patients Might Actually Pay

News reports and a company filing place the monthly list price near $39,800, which translates to about $477,000 per year. A morning show segment said out-of-pocket charges could vary and noted coupon programs for commercial plans, but those coupons do not apply to Medicare. The Pancreatic Cancer Action Network explained that after approval, Medicare and Medicaid usually cover the drug, but coverage still follows each payer’s rules. That means financial exposure will differ by plan, income, and program eligibility.

$RVMD — First FDA approval for Revolution Medicines. Daraxonrasib (Rasonque) is now approved for adults with metastatic pancreatic cancer. This validates the RVMD RAS-targeting platform, removing a major regulatory risk.

The approval is based on a 500-patient study. Rasonque…

— Banancial (@Banancial) August 26, 2026

Older Americans face the hardest math because most pancreatic cancer patients are over 65 and on Medicare, which limits coupon use and often ties costs to deductibles and coinsurance. Even with changes that lower out-of-pocket caps, timing and design details matter. The headline price rarely equals what insurers pay after rebates, and it rarely equals what a patient pays at the pharmacy. But the sticker still sets the tone for premiums and budgets. That is why insurers, taxpayers, and families all care where the list price lands.

What Families Should Do Next

Patients should ask their oncologist to confirm eligibility under the Food and Drug Administration label. Then call the insurer to get a benefits check for Rasonque using the brand and generic names. Ask for estimated monthly out-of-pocket costs and whether foundation help or manufacturer assistance applies. If on Medicare, ask about any caps, exceptions, and timing of coverage phases. These steps turn a scary headline into a plan. The right phone calls can cut real costs, or at least make them predictable.